What the specialists are actually looking at.
Part 6 of 8 in the Care4-Rare guided introduction. [ ← Three Confounded Syndromes ] [ Before You Say Yes → ]
If you arrived here directly and haven’t seen the two patient- developed graphics yet, they are in the sidebar — they show visually what this post explains in words.
[ Continue: Before You Say Yes → ]
When a vascular anomaly specialist orders an MRI, a Doppler ultrasound, a genetic panel, and a battery of follow-up studies, parents sometimes feel as though the medical system has swallowed their child whole.
The testing can feel disproportionate to what, from the outside, looks like a birthmark.
What I want to offer in this post is a window into what the specialist is actually doing — and why the testing is not excessive but essential.
— — —
There is a classification system. It is the foundation of modern care.
The International Society for the Study of Vascular Anomalies — the ISSVA — maintains the classification framework that vascular specialists worldwide use to diagnose, communicate about, and treat these conditions.
It is not a simple framework. It is necessarily complex because the conditions it describes are complex. But its underlying logic is straightforward:
Every vascular anomaly is first sorted by what it is doing — how blood is flowing, or not flowing, through the affected vessels — and then by what vessels are involved, what genetic drivers have been identified, and whether the condition is isolated or part of a broader syndrome.
The slow-flow section of the ISSVA classification — the section most relevant to port wine stains, KTS, and Sturge-Weber Syndrome — includes capillary malformations, venous malformations, lymphatic malformations, and combined malformations in dozens of specific presentations, each with its own name, its own associated syndromes, and its own implications for care.
When you look at the ISSVA slow-flow table included on this website, you are looking at the map the specialist is navigating.
— — —
This is why they order the studies they order.
An MRI can reveal whether there is venous malformation deeper than the skin. Doppler ultrasound can characterize whether blood flow is slow or fast, ruling high-flow arteriovenous shunting in or out. Genetic testing can identify specific mutations — PIK3CA, GNAQ, and others — that point toward specific diagnoses and specific treatment pathways.
None of these tests is looking for the port wine stain. The port wine stain is already visible. What they are looking for is what the port wine stain cannot tell them: the architecture, the physiology, the genetic instruction underlying the visible finding.
What you can see on the outside does not tell you what is happening underneath. These studies do.
This is not hypothetical caution. It is the lesson of a generation of patients — myself included — who were treated for what was visible before anyone confirmed what was actually present.
The classification exists because these conditions were once grouped together carelessly. The imaging exists because the eye, however experienced, cannot see blood flow. The genetics exist because the mutations driving these conditions have now been identified and can be tested for directly.
A specialist navigating this framework on your child’s behalf is doing something that was not possible when I was young. That is progress worth trusting — and worth insisting upon.
The final post brings the conversation to its most practical point: the treatment decisions that follow from all of this, and what it means to make those decisions with full information rather than incomplete ones.
Next: Post 5 — Before you say yes — the treatment conversation →
Care 4 - Rare 